Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
June 05, 2026 16:01 ET | Source: Jade Biosciences SAN FRANCISCO and…
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
May 29, 2026 16:05 ET | Source: Jade Biosciences SAN FRANCISCO and…
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
October 17, 2025 16:05 ET | Source: Jade Biosciences Presentations to highlight…
